Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Opsens Inc T.OPS

Alternate Symbol(s):  OPSSF

OpSens Inc. is engaged in physiological measurements such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and in transcatheter aortic valve replacement (TAVR) in the structural heart market. The Company supplies an optical-based pressure guidewire (OptoWire), a guidewire used in the TAVR procedure (SavvyWire) and a wide range of miniature optical sensors to measure pressure and temperature to be used in a wide range of applications that can be integrated into other medical devices.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RE:RE:RE:Regarding the 2 questions of the FDA

Thanks for the email chain between you and LL  rate and reply

RE:RE:Regarding the 2 questions of the FDA

Send me your email address by private message ill be glad to transfer the message i got from  Mr Laflamme.  rate and reply

RE:Regarding the 2 questions of the FDA

  I am surprised the CEO would have shared this with you directly in an email within 24 hours without the investors relations staff getting involved.   rate and reply

RE:Regarding the 2 questions of the FDA